Results 221 to 230 of about 43,229 (277)
Some of the next articles are maybe not open access.
Clinics in Liver Disease, 2003
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire +4 more sources
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire +4 more sources
Pegylated interferons for chronic hepatitis B
Antiviral Research, 2003Conventional interferon therapy has been used for the treatment of chronic hepatitis B (CHB) for many decades. However, the use of interferon has been limited by its short half-life and high incidence of dose-related side effects. A meta-analysis investigating the short- and long-term consequences of interferon therapy showed that, whilst interferon ...
Craxi, A., Cooksley, W. G.
openaire +3 more sources
Journal of Neuroscience Nursing, 2014
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend
Anne, Howley, Marcelo, Kremenchutzky
openaire +2 more sources
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend
Anne, Howley, Marcelo, Kremenchutzky
openaire +2 more sources
Ocular Immunology and Inflammation, 2023
To evaluate the efficacy of pegylated interferon (PEG-IFN) alpha-2a to treat post-uveitic relapsing macular edema (ME) after withdrawal of non-PEG IFN alpha-2a or 2b to maintain treatment efficacy.This retrospective study investigated subjects with post-uveitic ME who received weekly subcutaneous PEG-IFN alpha-2a injections.
De Simone L. +8 more
openaire +3 more sources
To evaluate the efficacy of pegylated interferon (PEG-IFN) alpha-2a to treat post-uveitic relapsing macular edema (ME) after withdrawal of non-PEG IFN alpha-2a or 2b to maintain treatment efficacy.This retrospective study investigated subjects with post-uveitic ME who received weekly subcutaneous PEG-IFN alpha-2a injections.
De Simone L. +8 more
openaire +3 more sources
Clinical Drug Investigation, 2014
Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner.Chronic hepatitis C patients ...
DURANTE MANGONI, Emanuele +7 more
openaire +3 more sources
Pegylated interferon (peg-IFN)-α2a and -α2b show different pharmacokinetic properties but are used interchangeably for hepatitis C treatment in traditional dual combinations and with newer agents. We assessed whether peg-IFN antiviral effects vary with peg-IFN subtype, affecting viral response in a differential manner.Chronic hepatitis C patients ...
DURANTE MANGONI, Emanuele +7 more
openaire +3 more sources
Early virologic response with pegylated interferons
Digestive and Liver Disease, 2004Recently, 12-week evaluation of viral response has been recommended as a means of reducing antiviral treatment morbidity and costs. The development of early stopping rules relies on an important assumption: rules must minimise discontinuation of treatment in patients who might ultimately respond after completion of the full course of therapy ...
openaire +2 more sources
Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C
Journal of Controlled Release, 2001Poly(ethyleneglycol) or PEG has proven to be of great value for a range of biomedical applications. A review the properties of PEG that lead to these applications is reported. Emphasis is placed on pharmaceutical uses of PEG--proteins, with specific discussion of the attributes of PEGylated alpha-interferon for treatment of hepatitis C.
A, Kozlowski, J M, Harris
openaire +2 more sources
Use of pegylated interferon in hypereosinophilic syndrome
Leukemia Research, 2012Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients.
Joseph H, Butterfield +1 more
openaire +2 more sources
Pegylated Interferon Monotherapy for Chronic Hepatitis C
Seminars in Liver Disease, 2004Interferon (IFN) alpha-2a has been attached to a branched 40-kD PEG molecule and IFN alpha-2b to a linear 12-kD PEG molecule leading to elimination half-lives of approximately 75 and approximately 30 hours, respectively. In one pivotal trial, 531 patients with chronic hepatitis C were assigned to receive either 180 microg of pegylated IFN alpha-2a once
Jenny, Heathcote, Stefan, Zeuzem
openaire +2 more sources
Pharmacokinetics of pegylated interferons: What is misleading?
Digestive and Liver Disease, 2004Available pegylated interferon (PEG-IFN) products confer enhanced therapeutic efficacy when compared with their IFN counterparts, and the added convenience of once-weekly dosing with no novel toxicities. PEG optimises the action of the IFNs by decreasing clearance rates, thereby allowing serum concentrations to remain constant over the dosing period ...
openaire +3 more sources